Related coverage linked through entity extraction aliases.
Aug 10, 2026
Alnylam reported Q4 2025 adjusted EPS of $1.25, beating estimates, while revenue of $1.10 billion missed consensus despite 85% growth. Amvuttra sales surged 189% to $826.6 million. The stock fell 4.1% after the mixed results.
Aug 05, 2026
Biotech funding roundup: $8M CIRM grant to Siren, $3.5M pre-seed for Claryx, Syntax Bio's $14.4M Series A, €80M Novo Nordisk Foundation programme, and Appili's NIAID contract termination.
Apr 30, 2026
In TRIDENT, GMRx2 reduced recurrent stroke risk by 39% after intracerebral hemorrhage. LT3001 was safe in phase 2 acute ischemic stroke trials, supporting a global phase 3.
Jul 22, 2026
Recent Rethinking Clinical Trials Grand Rounds sessions covered the COMPARE-Pediatric IBD study, a hypertension self-management texting intervention for Black Veterans, and the upcoming Pediatric Trials Network presentation.
Aug 04, 2026
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
Jun 30, 2026
Recent studies show that resistance training lowers cardiovascular disease risk in women, muscular strength is tied to lower mortality in older women, and both weekend warrior and regular exercise patterns reduce mortality in patients with hypertension.
Jul 10, 2026
Australian and US regulators have warned about sexual enhancement and honey products containing undeclared prescription medicines, prompting recalls and safety alerts. UK regulators also caution about underreported drug-herb interactions and herb-induced liver injury.
Jun 23, 2026
Duvakitug showed durable clinical and endoscopic efficacy over 44 weeks in UC and Crohn's patients in a phase 2b LTE study. The results reinforce duvakitug's potential as a best-in-class TL1A therapy. Both doses were well tolerated.
Jul 06, 2026
Hematologic cancer survivors face elevated CVD risk and fourfold higher heart failure risk. Cardiac screening is low among cardiotoxic treatment recipients. A trial found simple risk assessment may suffice.
Jun 06, 2026
Merck Foundation celebrated International Women's Day 2026 and hosted the 12th Africa Asia Luminary with African First Ladies, citing over 2,500 medical scholarships and 1,200 schoolgirl scholarships across Africa and Asia.
Jul 01, 2026
A study published in Menopause found that initiating hormone therapy after age 65 is associated with increased risks for any cancer and cerebrovascular accidents. The analysis of 83,147 women also showed elevated hazards for cancer and vascular events among those who initiated HT at ages 50 to 65.
Jul 13, 2026
A study finds that white matter disease detected on CT scans signals a higher risk for stroke or dementia compared to MRI-only findings. CT-detected WMD may represent more advanced cerebrovascular injury, highlighting the need for modality-specific interpretation of incidentally discovered brain abnormalities.
Jun 24, 2026
A case report describes eight-and-a-half syndrome in a 71-year-old man with hypertension and ischemic heart disease who presented with acute neurological deficits. MRI revealed an acute pontine infarction causing the characteristic triad of horizontal gaze palsy, internuclear ophthalmoplegia, and facial weakness.
Jun 10, 2026
The U.S. cardiovascular drugs market is projected to reach $37.03 billion by 2035, growing at a CAGR of 2.68%. Europe's anticoagulants market is expected to reach $23.68 billion by 2033, expanding at a CAGR of 8.22%.
May 18, 2026
Baxfendy was approved in the US for hypertension in adults not adequately controlled on other antihypertensive medicines. The approval was based on Phase III BaxHTN results showing significant systolic blood pressure reductions.
May 16, 2026
CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.
May 14, 2026
Alnylam Pharmaceuticals entered a $1.23 billion discovery collaboration with Tenaya Therapeutics to identify up to 15 novel genetic targets for heart disease. The agreement includes $10 million upfront and up to $1.13 billion in milestone payments.
May 14, 2026
The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.
May 13, 2026
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
May 04, 2026
The FDA said one pivotal trial plus confirmatory evidence will become the default standard for approval of most new drugs. The shift could extend beyond rare diseases to common conditions affecting millions.
